|
[1]HILL KR, RHODES K, STAFFORD JL, et al.Serous hepatosis:A pathogenesis of hepatic fibrosis in jamaican children[J].Br Med J, 1953, 1 (4802) :117-122.
|
|
[2]BRAS G, JELLIFFE DB, STUART KL.Veno-occlusive disease of liver with nonportal type of cirrhosis, occurring in Jamaica[J].AMA Arch Pathol, 1954, 57 (4) :285-300.
|
|
[3]DELEVE LD, MCCUSKEY RS, WANG X, et al.Characterization of a reproducible rat model of hepatic veno-occlusive disease[J].Hepatology, 1999, 29 (6) :1779-1791.
|
|
[4]DELEVE LD, SHULMAN HM, MCDONALD GB.Toxic injury to hepatic sinusoids:Sinusoidal obstruction syndrome (veno-occlusive disease) [J].Semin Liver Dis, 2002, 22 (1) :27-42.
|
|
[5]Cooperative Group for Hepatic and Gall Diseases, Chinese Society of Gastroenterology, Chinese Medical Association.Expert consensus on diagnosis and treatment of quinazoline alkaloids-related sinusoidal obstruction syndrome (2017, Nanjing) [J].J Clin Hepatol, 2017, 33 (9) :1627-1637. (in Chinese) 中华医学会消化病学分会肝胆疾病协作组.吡咯生物碱相关肝窦阻塞综合征诊断和治疗专家共识意见 (2017年, 南京) [J].临床肝胆病杂志, 2017, 33 (9) :1627-1637.
|
|
[6] HOU JG, XIA YT, YU CS, et al.Hepatic veno-occlusive disease:A report of 2 cases[J].Chin J Intern Med, 1980, 19:187-191. (in Chinese) 侯景贵, 夏玉亭, 余昌时, 等.肝小静脉闭塞病-附2例报告[J].中华内科杂志, 1980, 19:187-191.
|
|
[7]GUO Y, ZHANG SR, WEN LZ, et al.Clinical features of sinusoidal obstruction syndrome induced by pyrrolidine alkaloids in China[J].J Clin Hepatol, 2018, 34 (6) :1277-1281. (in Chinese) 郭严, 张世荣, 文良志, 等.我国吡咯烷生物碱致肝窦阻塞综合征的临床特征分析[J].临床肝胆病杂志, 2018, 34 (6) :1277-1281.
|
|
[8]PRAKASH AS, PEREIRA TN, REILLY PE, et al.Pyrrolizidine alkaloids in human diet[J].Mutat Res, 1999, 43 (1-2) :53-67.
|
|
[9]YANG M, RUAN J, GAO H, et al.First evidence of pyrrolizidine alkaloid N-oxide-induced hepatic sinusoidal obstruction syndrome in humans[J].Arch Toxicol, 2017, 91 (12) :3913-3925.
|
|
[10] CHEN Z, HUO JR.Hepatic veno-occlusive disease associated with toxicity of pyrrolizidine alkaloids in herbal preparations[J].Neth J Med, 2010, 68 (6) :252-260.
|
|
[11]WANG X, KANEL GC, DELEVE LD.Support of sinusoidal endothelial cell glutathione prevents hepatic veno-occlusive disease in the rat[J].Hepatology, 2000, 31 (2) :428-434.
|
|
[12]DELEVE LD, WANG X, TSAI J, et al.Sinusoidal obstruction syndrome (veno-occlusive disease) in the rat is prevented by matrix metalloproteinase inhibition[J].Gastroenterology, 2003, 125 (3) :882-890.
|
|
[13]YU XZ, JI T, BAI XL, et al.Expression of MMP-9 in hepatic sinusoidal obstruction syndrome induced by Gynura segetum[J].J Zhejiang Univ Sci B, 2013, 14 (1) :68-75.
|
|
[14]OKUNO M, HATANO E, NAKAMURA K, et al.Regorafenib suppresses sinusoidal obstruction syndrome in rats?[J].Surg Res, 2015, 193 (2) :693-703.
|
|
[15]CHEN Z, HUO JR.Hepatic veno-occlusive disease associated with toxicity of pyrrolizidine alkaloids in herbal preparations[J].Neth J Med, 2010, 68 (6) :252-260.
|
|
[16]WADLEIGH M, HO V, MOMTAZ P, et al.Hepatic veno-occlusive disease:Pathogenesis, diagnosis and treatment[J].Curr Opin Hematol, 2003, 10 (6) :451-462.
|
|
[17]ZHANG J, SHENG Y, LIANG S, et al.Quercetin and baicalein suppress monocrotaline-induced hepatic sinusoidal obstruction syndrome in rats[J].Eur J Pharmacol, 2017, 795:160-168.
|
|
[18]HARB R, XIE G, LUTZKO C, et al.Bone marrow progenitor cells repair rat hepatic sinusoidal endothelial cells after liver injury[J].Gastroenterology, 2009, 137 (2) :704-712.
|
|
[19]VALLA DC, CAZALSHATEM D.Sinusoidal obstruction syndrome[J].Clin Res Hepatol Gastroenterol, 2016, 14 (4) :651-658.
|
|
[20]SHULMAN HM, MCDONALD GB, MATTHEWS D, et al.An analysis of hepatic venocclusive disease and centrilobular hepatic degeneration following bone marrow transplantation[J].Gastroenterology, 1980, 79 (6) :1178-1191.
|
|
[21]CARRERAS E, BERTZ H, ARCESE W, et al.Incidence and outcome of hepatic veno-occlusive disease after blood or marrow transplantation:A prospective cohort study of the European Group for Blood and Marrow Transplantation.European Group for Blood and Marrow Transplantation Chronic Leukemia Working Party[J].Blood, 1998, 92 (10) :3599-3604.
|
|
[22]MOHTY M, MALARD F, ABECASSIS M, et al.Revised diagnosis and severity criteria for sinusoidal obstruction syndrome/veno-occlusive disease in adult patients:A new classification from the European Society for Blood and Marrow Transplantation[J].Bone Marrow Transplant, 2016, 51 (7) :906-912.
|
|
[23]DELEVE LD, VALLA DC, GARCIA-TSAO G.Vascular disorders of the liver[J].Hepatology, 2009, 49 (5) :1729-1764.
|
|
[24]FAN ZP, LIU ZL, LIN W, et al.Comparison of stem cell transplantation with pyrrolidene-associated hepatic venous occlusion syndrome[J].J Mod Med Health, 2018, 34 (13) :1949-1952, 1955. (in Chinese) 范作鹏, 刘贞利, 林伟, 等.干细胞移植与吡咯生物碱相关肝窦阻塞综合征的比较[J].现代医药卫生, 2018, 34 (13) :1949-1952, 1955.
|
|
[25]DEVARBHAVI H, SINGH R, PATIL M, et al.Outcome and determinants of mortality in 269 patients with combination antituberculosis drug-induced liver injury[J].J Gastroenterol Hepatol, 2013, 28 (1) :161-167.
|
|
[26]KIM J, JUNG Y.Radiation-induced liver disease:Current understanding and future perspectives[J].Exp Mol Med, 2017, 49 (7) :e359.
|
|
[27]DIGNAN FL, WYNN RF, HADZIC N, et al.BCSH/BSBMTguideline:Diagnosis and management of veno-occlusive disease (sinusoidal obstruction syndrome) following haematopoietic stem cell transplantation[J].Br J Haematol, 2013, 163 (4) :444-457.
|
|
[28]HAUSSMANN U, FISCHER J, EBER S, et al.Hepatic venoocclusive disease in pediatric stem cell transplantation:Impact of pre-emptive antithrombin III replacement and combined antithrombin III/defibrotide therapy[J].Haematologica, 2006, 91 (6) :795-800.
|
|
[29]NAKAMURA D, YOSHIMITSU M, KAWADA H, et al.Recombinant human soluble thrombomodulin for the treatment of hepatic sinusoidal obstructive syndrome post al ogeneic hematopoietic SCT[J].Bone Marrow Transplant, 2012, 47 (3) :463-464.
|
|
[30]YOON JH, MIN WS, KIM HJ, et al.Experiences of t-PA use in moderate-to-severe hepatic veno-occlusive disease after hematopoietic SCT:Is it still reasonable to use t-PA?[J].Bone Marrow Transplant, 2013, 48 (12) :1562-1568.
|
|
[31]WEISCHENDORFF S, KIELSEN K, SENGELOV H, et al.Associations between levels of insulin-like growth factor 1 and sinusoidal obstruction syndrome after allogeneic haematopoietic stem cell transplantation[J].Bone Marrow Transplant, 2017, 52 (6) :863.
|
|
[32]van CUTSEM E, CERVANTES A, NORDLINGER B, et al.Metastatic colorectal cancer:ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up[J].Ann Oncol, 2014, 25 (Suppl 3) :iii1-iii9.
|
|
[33]VIGANO L, CAPUSSOTTI L, DE RG, et al.Liver resection for colorectal metastases after chemotherapy:Impact of chemotherapy-related liver injuries, pathological tumor response, and micrometastases on long-term survival[J].Ann Surg, 2013, 258 (5) :731-740.
|
|
[34]NGUYENKHAC E, LOBRY C, CHATELAIN A, et al.A reappraisal of chemotherapy-induced liver injury in colorectal liver metastases before the era of antiangiogenics[J].Int J Hepatol, 2013, 2013:314868.
|
|
[35]RUBBIABRANDT L, AUDARD V, SARTORETTI P, et al.Severe hepatic sinusoidal obstruction associated with oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer[J].Ann Oncol, 2004, 15 (3) :460-466.
|
|
[36]RUBBIA-BRANDT L, LAUWERS GY, WANG H, et al.Sinusoidal obstruction syndrome and nodular regenerative hyperplasia are frequent oxaliplatin-associated liver lesions and partially prevented by bevacizumab in patients with hepatic colorectal metastasis[J].Histopathology, 2010, 56 (4) :430-439.
|
|
[37]HUBERT C, SEMPOUX C, HUMBLET Y, et al.Sinusoidal obstruction syndrome (SOS) related to chemotherapy for colorectal liver metastases:Factors predictive of severe SOS lesions and protective effect of bevacizumab[J].HPB, 2013, 15 (11) :858-864.
|
|
[38]ROBINSON SM, WILSON CH, BURT AD, et al.Chemotherapy-associated liver injury in patients with colorectal liver metastases:A systematic review and meta-analysis[J].Ann Surg Oncol, 2012, 19 (13) :4287-4299.
|
|
[39]van der POOL AE, MARSMAN HA, VERHEIJ J, et al.Effect of bevacizumab added preoperatively to oxaliplatin on liver injury and complications after resection of colorectal liver metastases[J].J Surg Oncol, 2012, 106 (7) :892-897.
|
|
[40]JAFARI A, MATTHAEI H, WEHNER S, et al.Bevacizumab exacerbates sinusoidal obstruction syndrome (SOS) in the animal model and increases MMP 9 production[J].Oncotarget, 2018, 9 (31) :21797-21810.
|
|
[41]ROBINSOM SM, MANN J, VASILAKI A, et al.Pathogenesis of FOLFOX induced sinusoidal obstruction syndrome in a murine chemotherapy model[J].J Hepatol, 2013, 59 (2) :318-326.
|
|
[42]RUBBIABRANDT L, TAUZIN S, BREZAULT C, et al.Gene expression profiling provides insights into pathways of oxaliplatinrelated sinusoidal obstruction syndrome in humans[J].Mol Cancer Ther, 2011, 10 (4) :687-696.
|
|
[43]AGOSTINI J, BENOIST S, SEMAN M, et al.Identification of molecular pathways involved in oxaliplatin-associated sinusoidal dilatation[J].J Hepatol, 2012, 56 (4) :869-876.
|
|
[44]ROBINSON SM, MANN DA, MANAS DM, et al.The potential contribution of tumour-related factors to the development of FOLFOX-induced sinusoidal obstruction syndrome[J].British J Cancer, 2013, 109 (9) :2396-2403.
|
|
[45]HIRATA M, TAJIMA H, MIYASHITA T, et al.Extravasated platelet aggregation in the livers of rats with druginduced hepatic sinusoidal obstruction syndrome[J].Mol Med Rep, 2017, 15 (5) :3147-3152.
|
|
[46]LEHMANN K, RICKENBACHER A, WEBER A, et al.Chemotherapy before liver resection of colorectal metastases:Friend or foe?[J].Ann Surg, 2012, 255:237-247.
|
|
[47]SOUBRANE O, BROUQUET A, ZALINSKI S, et al.Predicting high grade lesions of sinusoidal obstruction syndrome related to oxaliplatin-based chemotherapy for colorectal liver metastases:correlation with post-hepatectomy outcome[J].Ann Surg, 2010, 251 (3) :454-460.
|
|
[48]VREULS CP, MA VDB, WINSTANLEY A, et al.Hepatic sinusoidal obstruction syndrome (SOS) reduces the effect of oxaliplatin in colorectal liver metastases[J].Histopathology, 2012, 61 (6) :314-318.
|
|
[49]VREULS CP, OLDE DAMINK SW, KOEK GH, et al.Glutathione S-transferase M1-null genotype as risk factor for SOS in oxaliplatin-treated patients with metastatic colorectal cancer[J].Br J Cancer, 2013, 108 (3) :676-680.
|
|
[50]HAN NY, PARK BJ, SUNG DJ, et al.Chemotherapy-induced focal hepatopathy in patients with gastrointestinal malignancy:Gadoxetic acid-enhanced and diffusion-weighted MR imaging with clinical-pathologic correlation[J].Radiology, 2014, 271 (2) :416-425.
|
|
[51]TAKAMURA H, NAKANUMA S, HAYASHI H, et al.Severe veno-occlusive disease/sinusoidal obstruction syndrome after deceased-donor and living-donor liver transplantation[J].Transplant Proc, 2014, 46 (10) :3523-3535.
|
|
[52]WANG T, ONG P, ROSCIOLI T, et al.Hepatic veno-occlusive disease with immunodeficiency (VODI) :First reported case in the U.S.and identification of a unique mutation in Sp110[J].Clin Immunol, 2012, 145 (2) :102-107.
|
|
[53]MARQUARDSEN FA, BALDIN F, WUNDERER F, et al.Detection of Sp110 by flow cytometry and application to screening patients for veno-occlusive disease with immunodeficiency[J].Clin Immunol, 2017, 37 (7) :707-714.
|
|
[54]TALLMAN MS, MCDONALD GB, DELEVE LD, et al.Incidence of sinusoidal obstruction syndrome following Mylotarg (gemtuzumab ozogamicin) :A prospective observational study of 482 patients in routine clinical practice[J].Int J Hematol, 2013, 97 (4) :456-464.
|
DownLoad: